Japanese cedar and cypress pollinosis
Conditions
Interventions
Bepotastine besilate OD tablets administered to 14 subjects at twice daily the day before Japanese cedar pollen exposure. The next day(day of Japanese cedar pollen exposure) also administered twice d
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CAP-RAST score against Japanese cedar pollen and cypress pollen over 2 within the last 3 years. 2) Patients who have typical seasonal allergic rhinitis symptoms for at least 2 years. 3) Patients who are considered eligible medical examination results investigator doctors. 4) Written informed consent is required.
Exclusion criteria
Exclusion criteria: 1) Some patients with mucosal lesion of the nose and eyes. 2) Patients with severe perennial allergic rhinitis or requiring treatment. 3) Patients who received steroid injections within 6 months. 4) Patients with respiratory disease such as asthma. 5) Patients with past history of anaphylaxis. 6) Patients who have the hypersensitivity to study drug. 7) Pregnancy, breast-feeding woman, potential pregnancy, patients who wish to become pregnant during this study. 8) Patients who were judged to be unsuitabele for patinet enrollment by their doctor(Patients who have undergone nasal operation or patients who have undergone immunotherapy).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms score(Nasal, Ocular, Oropharyngeal) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Occurrence time of the first nasal symptom or the first ocular symptom 2) Nasal secretion volume 3) No of sneezing 4) Digit cancellation test | — |
Countries
Japan
Contacts
Public ContactKiyochika Suematsu
Medical Corporation Shinanokai, Samoncho Clinic Pharmaceutical Dept.,
Outcome results
None listed